Laurus Labs Ltd (BOM:540222) has kicked off the financial year with an impressive 31% year-on-year growth in total income, fueled by a surge in demand in the CDMO and generic divisions. The company’s recent earnings call revealed exciting updates on various capacity expansions and advancements in their biotech operations. Dr. Chava discussed the installation of 400 kiloliters of fermentation capacity in Vizag as Phase 1, with ambitious plans to scale up to 2 million liters in subsequent phases. With a keen focus on proteins and polymers produced through fermentation, Laurus Bio is poised for significant growth and innovation in the food proteins sector.
Gross margins have expanded to 59%, driven by a better product mix and process improvements, while EBITDA margin has seen improvement to 25%, showcasing enhanced operating leverage and product offerings. The company’s CDMO business experienced remarkable growth, with sales hitting INR493 crores, primarily attributed to mid- to late-stage NCE deliveries and the integration of new manufacturing assets. Additionally, Laurus Labs Ltd has successfully undergone 39 quality audits without any critical findings, underscoring their commitment to regulatory compliance and industry standards. The recent developments indicate a promising future for Laurus Labs Ltd as they continue to expand their presence in the biotech sector and explore new growth opportunities.
Read more from finance.yahoo.com